{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:35:09Z","timestamp":1794555309908,"version":"4.9.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review the latest data in the field of vaccinations in systemic lupus erythematosus (SLE), focusing on pneumococcal, seasonal influenza, herpes zoster and human papillomavirus infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Less than 40% of patients responded adequately to the 23-valent pneumococcal polysaccharide (PPS23) vaccine. A randomized controlled trial showed that sequential administration of the pneumococcal conjugate vaccine followed by the PPS23 vaccine was well tolerated but was not superior to the PPS23 vaccine alone in terms of immunogenicity. A real-life observation confirmed that annual influenza vaccination has an impact on morbidity and mortality in SLE. Three meta-analyses did not show any particular adverse effect of influenza vaccines in SLE. These vaccines are less immunogenic in SLE. A study confirmed that the quadrivalent human papillomavirus vaccine was well tolerated and highly immunogenic in SLE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>New data confirm the safety and the lower immunogenicity of pneumococcal and influenza vaccine in SLE patients. Current efforts to improve immunization coverage in SLE should focus on spreading to patients and physicians information on the safety, efficacy and usefulness of vaccines in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000525","type":"journal-article","created":{"date-parts":[[2018,6,10]],"date-time":"2018-06-10T17:24:22Z","timestamp":1528651462000},"page":"465-470","source":"Crossref","is-referenced-by-count":20,"title":["Lupus and vaccinations"],"prefix":"10.1097","volume":"30","author":[{"given":"Alexis","family":"Mathian","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 2, French National Reference Center for Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome, Institut E3M, Groupement Hospitalier Piti\u00e9 Salp\u00eatri\u00e8re, Assistance Publique H\u00f4pitaux de Paris (AP-HP)"},{"name":"Sorbonne Universit\u00e9, INSERM, Centre d\u2019Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"Pha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, French National Reference Center for Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome, Institut E3M, Groupement Hospitalier Piti\u00e9 Salp\u00eatri\u00e8re, Assistance Publique H\u00f4pitaux de Paris (AP-HP)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, French National Reference Center for Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome, Institut E3M, Groupement Hospitalier Piti\u00e9 Salp\u00eatri\u00e8re, Assistance Publique H\u00f4pitaux de Paris (AP-HP)"},{"name":"Sorbonne Universit\u00e9, INSERM, Centre d\u2019Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"Rua-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.revmed.2016.01.005","article-title":"Prevention of infections in adults and adolescents with systemic lupus erythematosus: guidelines for the clinical practice based on the literature and expert opinion","volume":"37","author":"Mathian","year":"2016","journal-title":"Rev Med Interne"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/0961203316636472","article-title":"Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment","volume":"25","author":"Rezende","year":"2016","journal-title":"Lupus"},{"key":"R6-20230829","first-page":"204","article-title":"Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus","volume":"13","author":"Alyasin","year":"2016","journal-title":"Iran J Immunol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/0961203317695465","article-title":"Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine","volume":"26","author":"Nagel","year":"2017","journal-title":"Lupus"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2017.07.094","article-title":"Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study","volume":"35","author":"Grabar","year":"2017","journal-title":"Vaccine"},{"key":"R10-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212789","article-title":"Impaired long-term immune protection following pneumococcal 13-valent\/23-valent polysaccharide vaccine in systemic lupus erythematosus (SLE)","author":"Sacre","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.vaccine.2017.04.001","article-title":"The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus","volume":"35","author":"Dhar","year":"2017","journal-title":"Vaccine"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2017.05.012","article-title":"Pneumococcal infection in patients with systemic lupus erythematosus","volume":"85","author":"Schurder","year":"2018","journal-title":"Joint Bone Spine"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00296-017-3872-5","article-title":"Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus?","volume":"38","author":"Uskudar Cansu","year":"2018","journal-title":"Rheumatol Int"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"37817","DOI":"10.1038\/srep37817","article-title":"Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"e3637","DOI":"10.1097\/MD.0000000000003637","article-title":"Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination?: a systematic review and meta-analysis","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","article-title":"Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis","volume":"55","author":"Puges","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"e0147856","DOI":"10.1371\/journal.pone.0147856","article-title":"Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kep200","article-title":"Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study","volume":"48","author":"Holvast","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.30576","article-title":"Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus","volume":"63","author":"Mathian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: a systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"e0144918","DOI":"10.1371\/journal.pone.0144918","article-title":"National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia","volume":"11","author":"Murray","year":"2016","journal-title":"PLoS One"},{"key":"R22-20230829","first-page":"6222","article-title":"Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors","volume":"14","author":"Chen","year":"2017","journal-title":"Exp Ther Med"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaad.2015.12.059","article-title":"Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): a nationwide case-control study","volume":"75","author":"Hu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an antiinterferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an antiinterferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in SLE: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case\u2013control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-11-29","article-title":"Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years","volume":"11","author":"Soybilgic","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3899\/jrheum.130246","article-title":"Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis","volume":"40","author":"Heijstek","year":"2013","journal-title":"J Rheumatol"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16\u201326 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"R34-20230829","article-title":"Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic","author":"Krasselt","year":"2017","journal-title":"Z Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2015.01.002","article-title":"Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus","volume":"44","author":"Lawson","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2014-2512","article-title":"Improving pneumococcal vaccination in pediatric rheumatology patients","volume":"136","author":"Harris","year":"2015","journal-title":"Pediatrics"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ejim.2017.05.023","article-title":"Nurse-led vaccination program dramatically improves pneumococcal vaccination coverage among patients with autoimmune inflammatory disorders","volume":"43","author":"Serre","year":"2017","journal-title":"Eur J Intern Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201809000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:37:39Z","timestamp":1693291059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201809000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000525","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}